sulphoraphene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sulphoraphene: from radish; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6433206
CHEMBL ID	49659
SCHEMBL ID	2937706
MeSH ID	M0449015

Synonyms (27)

Synonym
unii-nco9mc39io
nco9mc39io ,
sulphoraphene
isothiocyanic acid, 4-(methylsulfinyl)-3-butenyl ester
sulforaphene
1-butene, 4-isothiocyanato-1-(methylsulfinyl)-
raphanin
sulforaphen
4-isothiocyanato-1-(methylsulfinyl)-1-butene
sulphoraphen
CHEMBL49659
592-95-0
(e)-4-isothiocyanato-1-methylsulfinylbut-1-ene
AKOS006274434
SCHEMBL2937706
AC-34422
(1e)-4-isothiocyanato-1-methanesulfinylbut-1-ene
(r)-(e)-sulforaphene
s-sulforaphene ,
HY-N2450
F21504
Q7294040
1-methylsulfinylbutenyl isothiocyante
CS-0022676
MS-22937
(-)4-isothiocyanato-4r-(methylsulfinyl)-1-butene
AKOS040760048

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" This novel LC-MS-MS method shows satisfactory accuracy and precision and is sufficiently sensitive for the performance of pharmacokinetic studies in rats."	( Development and validation of an LC-MS-MS method for the simultaneous determination of sulforaphane and its metabolites in rat plasma and its application in pharmacokinetic studies. Khor, TO; Kong, AN; Lin, W; Nomeir, AA; Shen, G; Wang, H, )	0.13

Bioavailability

Excerpt	Reference	Relevance
"The evaluation of the bioavailability of bioactive compounds from cruciferous foods is one challenge in the design of clinical trials for studying their functionality."	( Bioavailability and new biomarkers of cruciferous sprouts consumption. Baenas, N; García-Viguera, C; Moreno, DA; Suárez-Martínez, C, 2017)	0.46
" However, chemopreventive metabolites are typically inactive and have low bioavailability and poor host absorption."	( Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Chang, MW; Chua, KJ; Ho, CL; Kang, A; Lee, YS; Lim, KH; Ling, KL; Tan, HQ; Thiery, JP; Yew, WS, 2018)	0.48

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Quinone oxidoreductase	Mus musculus (house mouse)	CD	0.4000	0.2000	2.7421	9.8000	AID163303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay ID	Title	Year	Journal	Article
AID1418252	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418268	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 8 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 67.26%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418270	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 8 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 24.78%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418253	Drug degradation in methanol after 10 hrs at 50 degC by HPLC analysis	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418250	Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418266	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 4 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 7.96%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418247	Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell proliferation at 32 uM after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418261	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 6.76%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418245	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation at 32 uM after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418244	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation at 16 uM after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418256	Inhibition of colony formation in human SMMC7721 cells at 2 to 8 uM after 7 days by crystal violet staining-based assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418265	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 4 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 67.26%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418249	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418267	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 4 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 24.78%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418248	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID163303	In vitro potency to induce quinone reductase activity in murine hepatoma cells was determined	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Design and synthesis of bifunctional isothiocyanate analogs of sulforaphane: correlation between structure and potency as inducers of anticarcinogenic detoxication enzymes.
AID1418264	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 91.92%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418262	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.62%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418258	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.62%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418246	Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell proliferation at 16 uM after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418263	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.70%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418259	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.70%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418260	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 91.92%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418257	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 6.76%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418251	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418269	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 8 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 7.96%)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (1.96)	18.7374
1990's	1 (1.96)	18.2507
2000's	3 (5.88)	29.6817
2010's	31 (60.78)	24.3611
2020's	15 (29.41)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	46.58 (24.57)
Research Supply Index	3.97 (2.92)
Research Growth Index	5.93 (4.65)
Search Engine Demand Index	138.47 (26.88)
Search Engine Supply Index	4.00 (0.95)

This Compound (46.58)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	52 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.13	1	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
3,3'-diindolylmethane 3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist	3.06	1	indoles	antineoplastic agent; P450 inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.03	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	4.53	8	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	2.13	1	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.53	2	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
phenethyl isothiocyanate phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.	2.46	2	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.21	1	copper group element atom; elemental gold
etoposide [no description available]	2.05	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
chlorodiphenyl (54% chlorine) Chlorodiphenyl (54% Chlorine): A mixture of polychlorinated biphenyls that induces hepatic microsomal UDP-glucuronyl transferase activity towards thyroxine.. Aroclor 1254 : A mixture of polychlorobiphenyls of unspecified composition, containing 54% chlorine (X = Cl or H).	2.01	1
isothiocyanic acid [no description available]	2.86	3	hydracid; one-carbon compound
erucin [no description available]	2.53	2	isothiocyanate
4-(methylthio)-3-butenyl isothiocyanate 4-(methylthio)-3-butenyl isothiocyanate: structure in first source	2.06	1
lapatinib [no description available]	2.53	2	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
trovafloxacin glucoraphenin : A glucosinolic acid that consists of 1-thio-beta-D-glucopyranose attached to a 1-(methylsulfinyl)-5-[(sulfooxy)imino]pent-1-en-5-yl group at the anomeric sulfur.	3.09	4
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.13	1	cysteinium	fundamental metabolite
4-methylthio-3-butenyl glucosinolate 4-methylthio-3-butenyl glucosinolate: from Raphanus sativus sprouts; structure in first source	2.06	1
glucoraphanin glucoraphanin: precursor of sulforaphane. glucoraphanin : A thia-glucosinolic acid that is glucoerucin in which the sulfur atom of the methyl thioether group has been oxidised to the corresponding sulfoxide.	2.6	1	sulfoxide; thia-alkylglucosinolic acid
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.11	1
chitosan [no description available]	2.21	1

Condition	Relationship Strength	Studies
Experimental Hepatoma [description not available]	1.98	1
Acne [description not available]	4.02	9
Innate Inflammatory Response [description not available]	4.02	9
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	4.02	9
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	4.02	9
Acute Confusional Senile Dementia [description not available]	3.52	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.57	6
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.52	4
Rheumatoid Arthritis [description not available]	2.6	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.6	1
Bone Loss, Osteoclastic [description not available]	2.6	1
Pericementitis [description not available]	2.6	1
Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)	2.6	1
Adenocarcinoma, Endometrioid [description not available]	2.6	1
Epithelial Ovarian Cancer [description not available]	2.6	1
Cancer of Ovary [description not available]	2.61	2
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	2.6	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.61	2
Carcinoma, Endometrioid An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.	2.6	1
Disease Exacerbation [description not available]	2.94	3
Cancer of Esophagus [description not available]	2.25	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.25	1
Bone Cancer [description not available]	2.25	1
Osteogenic Sarcoma [description not available]	2.25	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.25	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.25	1
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	2.25	1
Breast Cancer [description not available]	3.24	5
Breast Neoplasms Tumors or cancer of the human BREAST.	3.24	5
Germinoblastoma [description not available]	2.17	1
Benign Neoplasms [description not available]	2.48	2
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.17	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.48	2
Thyroid Cancer, Anaplastic [description not available]	2.17	1
Cancer of the Thyroid [description not available]	2.17	1
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.17	1
Thyroid Carcinoma, Anaplastic An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.	2.17	1
Colorectal Cancer [description not available]	2.58	2
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.58	2
Fish Diseases Diseases of freshwater, marine, hatchery or aquarium fish. This term includes diseases of both teleosts (true fish) and elasmobranchs (sharks, rays and skates).	2.1	1
Infections, Rhabdoviridae [description not available]	2.1	1
Cancer of Stomach [description not available]	2.13	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.13	1
Cancer of Colon [description not available]	2.13	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.13	1
Invasiveness, Neoplasm [description not available]	2.13	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.13	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.13	1
Cancer of Lung [description not available]	2.13	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.13	1
Cancer of Cervix [description not available]	2.05	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.05	1
Anasarca [description not available]	2.06	1
Myelopathy [description not available]	2.06	1
Injuries, Spinal Cord [description not available]	2.06	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.06	1
Spinal Cord Diseases Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.	2.06	1
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	2.06	1

chemdatabank.com